CINCINNATI, May 26, 2022
/PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading
global provider of diagnostic testing solutions and life science
raw materials, announced today that its inhibitor-tolerant qPCR
master mixes are ideal for the development of fast, accurate and
highly sensitive qPCR monkeypox virus (monkeypox) molecular
diagnostic tests.
The recent outbreak of monkeypox has caused global concern due
to its unprecedented rapid spread, resulting in what is feared to
be the largest outbreak outside of Africa. Monkeypox is an orthopoxvirus first
identified in monkeys and has historically only circulated in
central and west Africa. Since
May 13, 2022, more than 250 monkeypox
cases have been reported to the World Health Organization (WHO)
from 17 countries outside of Africa, with no known direct travel links to
endemic areas.
Screening assays that detect low levels of the virus will be
instrumental in helping to contain the outbreak as it continues to
spread globally. Monkeypox has a long incubation period of up
to three weeks, making traditional viral culture techniques not
ideal for testing for monkeypox. Serology testing is also
challenging due to the close antigenic relation between surface
antigens among the orthopoxviruses. Therefore, confirmation of
monkeypox infection requires qPCR detection, which is considered
the most rapid, sensitive, and accurate method for viral
diagnosis. Meridian has identified its inhibitor-tolerant
qPCR master mixes as the best molecular master mixes in the
portfolio for the detection of monkeypox. These mixes have
versions compatible with either wet or dry assay formats with its
Lyo-ready™ (lyophilization ready) or Air-dryable™
technologies.
"With any outbreak, it's critical to bring accurate testing to
healthcare professionals as quickly as possible. Meridian
helped bring over 100 COVID-19 tests to market, including dozens in
the early months of the pandemic, and is prepared to support
diagnostic manufacturers in developing assays for monkeypox,"
commented Lourdes Weltzien, Ph.D.
Executive Vice President - Life Science. "Our
inhibitor-tolerant qPCR mixes are perfect for developing monkeypox
assays without the need for further optimization, greatly reducing
development time. Our team is standing by to help customers
identify the best master mix for their application."
Meridian continues to be steadfast in its commitment to bringing
innovation and quality products to the IVD community, with a focus
on developing tools that improve assay accuracy, increase
operational efficiencies, and reduce overall costs to enable
screening assays that are fast and affordable. To learn more about
Meridian's innovative products, visit
www.meridianlifescience.com/molecular-dx-reagents or contact
Paul.Marr@meridianlifescience.com.
About Meridian Bioscience, Inc.
Meridian is a fully
integrated life science company that develops, manufactures,
markets, and distributes a broad range of innovative diagnostic
products. We are dedicated to developing and delivering better
solutions that give answers with speed, accuracy, and simplicity
that are redefining the possibilities of life from discovery to
diagnosis. Through discovery and development, we provide critical
life science raw materials used in immunological and molecular
tests for human, animal, plant, and environmental applications.
Through diagnosis, we provide diagnostic solutions in areas
including gastrointestinal and upper respiratory infections and
blood lead level testing. We build relationships and provide
solutions to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics
manufacturers, and biotech companies in more than 70 countries
around the world.
Meridian's shares are traded on the NASDAQ Global Select Market,
symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-responds-to-the-monkeypox-outbreak-with-its-inhibitor-tolerant-qpcr-master-mixes-for-the-development-of-molecular-tests-301556096.html
SOURCE Meridian Bioscience, Inc.
